Prevention of human immunodeficiency virus breastmilk transmission with copper oxide: proof-of-concept study

Breastfeed Med. 2011 Aug;6(4):165-70. doi: 10.1089/bfm.2010.0090.

Abstract

Background: Human immunodeficiency virus type 1 (HIV-1) transmission through breastmilk is the chief modality through which HIV-1 is transmitted from HIV-1-infected mothers to their babies in developing countries, where alternative feeding options lack practical feasibility. The development of an approach to inactivate the HIV-1 virions ingested by an infant on a daily basis through breastmilk is thus of critical importance.

Methods: Copper has potent virucidal properties. Stoichiometric concentrations of copper ions inactivate the HIV-1 protease, which is essential for viral replication. Cell-free and cell-associated HIV-1 infectivity is inhibited when the virus is exposed to copper oxide in a dose-dependent manner. Passage of high titers of a wide range of HIV-1 isolates, spiked in culture medium, through filters containing copper oxide powder resulted in their deactivation.

Results: In the current study, we demonstrate that the infectivity of three different HIV-1 isolates, spiked in breastmilk obtained from HIV-1-seronegative donors, or of wild-type isolates found in breastmilk obtained from HIV-1-seropositive donors, is drastically reduced (>98%) when exposed to copper oxide.

Conclusions: This study is proof of concept that copper oxide is efficacious against HIV-1 found in breastmilk and serves as the basis for further research aimed at determining the possible effects that copper may have on the nutritional and anti-infective properties of breastmilk. Furthermore, this supports the continuing study of the feasibility of developing a filtering device, such as an "at-the-breast" disposable shield that can be used discreetly and safely by HIV-1-infected mothers during breastfeeding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Feeding / adverse effects
  • Copper / adverse effects
  • Copper / pharmacology*
  • Developing Countries
  • Equipment Design
  • Female
  • Filtration / instrumentation*
  • HIV Infections* / prevention & control
  • HIV Infections* / transmission
  • HIV Protease / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / enzymology
  • HIV-1 / pathogenicity
  • Humans
  • Infant
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Milk, Human / virology
  • Powders
  • Trace Elements / adverse effects
  • Trace Elements / pharmacology
  • Treatment Outcome
  • Virus Inactivation / drug effects
  • Virus Replication / drug effects

Substances

  • Powders
  • Trace Elements
  • Copper
  • HIV Protease
  • p16 protease, Human immunodeficiency virus 1
  • cuprous oxide